AbbVie: towards innovative therapies with “Alfons”

Home  >>  News  >>  AbbVie: towards innovative therapies with “Alfons”

AbbVie: towards innovative therapies with “Alfons”

On January 15, 2019, Posted by , In News, By , , With Comments Off on AbbVie: towards innovative therapies with “Alfons”

What does the future of research actually look like? Alfons” gives an answer to this question. What sounds like a first name that has gone out of fashion stands for the finest in high technology. “Automated Liquid Formulation Screening” is a real innovation: Using the data generated with this system, scientists can, among other things, calculate how a certain biopharmaceutical active ingredient behaves. This field of mathematical simulations is called ‘predictive analytics’. And with every experiment, scientists learn more thanks to the intelligent solution for laboratory automation. In an interview, AbbVie researcher Michael Siedler (Research Fellow and Haed of the High Throughput Screening and Advanced Formulation Sciences Department, AbbVie in Ludwigshafen) explains exactly what this means for patients and research into new therapies.

Read here the complete interview (in German).

Related Post

Comments are closed.